Page 9 - Sciences Ltd News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Roivant Sciences Investors Score Big Today

Immunovant (NASDAQ:IMVT – Free Report) had its price target hoisted by Cantor Fitzgerald from $30.00 to $45.00 in a report issued on Monday, Benzinga reports. They currently have an overweight rating on the stock. A number of other research analysts have also commented on the stock. UBS Group upgraded shares of Immunovant from a neutral […]

Roivant Sciences Ltd. (NASDAQ:ROIV – Get Free Report) has received an average recommendation of “Moderate Buy” from the nine research firms that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12 […]

Roivant Sciences Ltd. (NASDAQ:ROIV – Get Free Report) COO Eric Venker sold 153,027 shares of the company’s stock in a transaction dated Thursday, October 5th. The shares were sold at an average price of $10.11, for a total value of $1,547,102.97. Following the completion of the transaction, the chief operating officer now owns 595,397 shares […]

Acumen Research and Consulting recently published report titled “Human Growth Hormone Market Forecast, 2023 - 2032”...